Department of Biology, University of Rome Tor Vergata, Rome, Italy.
Tumor Immunology Unit, Department of Health Sciences, University of Palermo School of Medicine, Palermo, Italy.
Mol Oncol. 2022 Jan;16(1):188-205. doi: 10.1002/1878-0261.13103. Epub 2021 Oct 14.
Programmed cell death-1 (PD-1) signaling downregulates the T-cell response, promoting an exhausted state in tumor-infiltrating T cells, through mostly unveiled molecular mechanisms. Dynamin-related protein-1 (Drp1)-dependent mitochondrial fission plays a crucial role in sustaining T-cell motility, proliferation, survival, and glycolytic engagement. Interestingly, such processes are exactly those inhibited by PD-1 in tumor-infiltrating T cells. Here, we show that PD-1 CD8 T cells infiltrating an MC38 (murine adenocarcinoma)-derived murine tumor mass have a downregulated Drp1 activity and more elongated mitochondria compared with PD-1 counterparts. Also, PD-1 lymphocytic elements infiltrating a human colon cancer rarely express active Drp1. Mechanistically, PD-1 signaling directly prevents mitochondrial fragmentation following T-cell stimulation by downregulating Drp1 phosphorylation on Ser616, via regulation of the ERK1/2 and mTOR pathways. In addition, downregulation of Drp1 activity in tumor-infiltrating PD-1 CD8 T cells seems to be a mechanism exploited by PD-1 signaling to reduce motility and proliferation of these cells. Overall, our data indicate that the modulation of Drp1 activity in tumor-infiltrating T cells may become a valuable target to ameliorate the anticancer immune response in future immunotherapy approaches.
程序性细胞死亡受体 1(PD-1)信号通路通过尚未完全揭示的分子机制下调 T 细胞反应,导致肿瘤浸润 T 细胞处于耗竭状态。与 T 细胞运动、增殖、存活和糖酵解相关的动力相关蛋白 1(Drp1)依赖性线粒体裂变起着至关重要的作用。有趣的是,这些过程正是 PD-1 在肿瘤浸润 T 细胞中抑制的过程。在这里,我们发现与 PD-1 对应的细胞相比,浸润 MC38(鼠腺癌)衍生的鼠肿瘤块的 PD-1 CD8 T 细胞的 Drp1 活性降低,线粒体更加细长。此外,浸润人结肠癌的 PD-1 淋巴细胞很少表达活性 Drp1。从机制上讲,PD-1 信号通过下调 Drp1 丝氨酸 616 上的磷酸化,通过调节 ERK1/2 和 mTOR 途径,直接防止 T 细胞刺激后的线粒体碎片化。此外,肿瘤浸润 PD-1 CD8 T 细胞中 Drp1 活性的下调似乎是 PD-1 信号降低这些细胞运动和增殖的一种机制。总的来说,我们的数据表明,调节肿瘤浸润 T 细胞中的 Drp1 活性可能成为改善未来免疫治疗方法中抗癌免疫反应的有价值的靶点。